🔴 Adaptive Biotechnologies is trading 5% down today as investors consolidate gains following its $300 million debt offering rally

Adaptive Biotechnologies is trading at $20.00, down 5% in after-hours as investors consolidate gains following a sharp rally driven by strategic business shifts and a debt offering.

• The stock is extending a 3.4% regular-session decline from $21.06, reflecting cooling volatility after news of an upsized $300 million 0% convertible notes offering.
• Markets are reassessing potential dilution and execution risks associated with the company's plan to separate its MRD and Immune Medicine businesses.